SOCM
SR One Capital Management Portfolio holdings
AUM
$461M
This Quarter Return
-5.41%
1 Year Return
+23.25%
3 Year Return
+188.96%
5 Year Return
–
10 Year Return
–
AUM
$389M
AUM Growth
+$389M
(-5.1%)
Cap. Flow
+$23.8M
Cap. Flow
% of AUM
6.11%
Top 10 Holdings %
Top 10 Hldgs %
98.26%
Holding
12
New
1
Increased
1
Reduced
–
Closed
–
Top Buys
| 1 |
Mineralys Therapeutics
MLYS
|
$17.6M |
| 2 |
Oculis Holding
OCS
|
$6.14M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Arcellx
ACLX
$3.88B
| $154M | 39.54% |
2,346,630
| – | – |
|
2
ARS Pharmaceuticals
SPRY
$1.08B
| $50.5M | 12.97% |
4,012,903
| – | – |
|
|
3
Mineralys Therapeutics
MLYS
$1.92B
| $49.7M | 12.76% |
3,127,933
+1,111,111
| +55% | +$17.6M |
|
|
ZBIO
4
Zenas BioPharma, Inc. Common Stock
ZBIO
$723M
| $38.8M | 9.97% |
4,911,539
| – | – |
|
5
CRISPR Therapeutics
CRSP
$4.79B
| $35.7M | 9.17% |
1,048,951
| – | – |
|
6
Design Therapeutics
DSGN
$339M
| $25.2M | 6.47% |
6,526,476
| – | – |
|
|
ALMS
7
Alumis Inc. Common Stock
ALMS
$483M
| $12M | 3.09% |
1,959,896
| – | – |
|
|
8
Oculis Holding
OCS
$850M
| $6.14M | 1.58% |
+322,500
| New | +$6.14M |
|
9
Nkarta
NKTX
$148M
| $6.13M | 1.58% |
3,333,333
| – | – |
|
|
ORKA
10
Oruka Therapeutics, Inc. Common Stock
ORKA
$580M
| $4.42M | 1.13% |
430,330
| – | – |
|
11
KALA BIO
KALA
$97M
| $3.43M | 0.88% |
598,940
| – | – |
|
12
enGene Holdings
ENGN
$228M
| $3.35M | 0.86% |
747,750
| – | – |
|